The Food and Drug Administration recently approved a simple blood test to screen for colorectal cancer when it is still in its early stages and usually curable. Medicare will now pay the cost of this new test for seniors. But it will likely be years before private insurers cover it for younger people, among whom there has been an alarming rise in the appearance of the disease.

Whether insurance companies are required to pay for any type of preventive care is in the hands of a little-known volunteer panel of 16 experts, whose approximately $11 million budget is preposterously inadequate to the growing size of their mission.

Too small and unfunded

The U.S. Preventive Services Task Force (USPSTF) was created in 1984 as an independent advisory group to evaluate scientific evidence on preventive measures and develop recommendations for primary care providers to follow. It weighs in on more than 80 topics, as varied as behavioral counseling, preventive medications, and screenings for mental and physical illnesses and domestic violence.

Its role expanded dramatically with the 2010 passage of the Affordable Care Act, which requires that insurance companies cover the total cost of any preventive care that receives an A or a B grade from the USPSTF.

Advertise with us

Funding for the task force has remained stagnant, however, which means it lacks the resources to make its evaluations in a timely manner. It’s also reasonable to wonder why so much work is being assigned to a group of volunteers who have practically no staff and meet in person only three times a year.

AmirAli Talasaz, co-CEO of Guardant Health, which developed the new test, noted that the task force recommendations “set the commercial coverage pathway, but this last mile [the time it takes for the task force to act after the FDA approves a new treatment] generates potential delays in patient access of five years or more.”

Rep. Anna G. Eshoo, the ranking Democrat on the Energy and Commerce health subcommittee, has for years been leading a bipartisan effort on Capitol Hill to get additional money for the USPSTF. But, she said, “I haven’t been able to move the needle.”

Caught in the culture wars

In fact, House Republicans have tried in their budgets to eliminate entirely the government arm that supports the task force, the Health and Human Services Department’s Agency for Healthcare Research and Quality.

Some of this opposition is related to a court case, Braidwood Management Inc. v. Becerra, filed by a group of conservative plaintiffs who challenge the constitutionality of the task force’s role in mandating what private insurance policies cover.

Advertise with us

A group of Christian-owned businesses and individuals have expressed religious objections to being required to buy health insurance that covers USPSTF-recommended measures such as PrEP (pre-exposure prophylaxis) to prevent HIV transmission and screenings for sexually transmitted disease. They claim that these measures “facilitate and encourage homosexual behavior, intravenous drug use, and sexual activity outside of marriage between one man and one woman.”

Even as the task force’s evidence-based mission is entangled in the culture wars, science is continuing to find new ways to combat unnecessary deaths from a host of illnesses — including colorectal cancer.

This year, more than 53,000 people are expected to die of this disease. For reasons that medical experts can’t explain, a disease that once was relatively rare among the non-elderly has become the leading cause of cancer death for men under 50, and the second-highest for women that age group.

The USPSTF now advises that screenings, either by sensitive fecal tests or visualization methods such as colonoscopies and flexible sigmoidoscopy, should begin as early as age 45.

But not enough people are getting tested. Research has shown that more than three-quarters of people who die of colon cancer did not receive the recommended screening.

Advertise with us

The new test, which is called Shield and currently costs $895 for people who pay for it out of pocket, works by finding the genetic material that a tumor sheds into the bloodstream. It is not a perfect substitute for a colonoscopy, but the test could easily be incorporated into an annual physical, which means that more people would get it.

Scientific miracles

More significantly, this type of screening represents the future of fighting cancer. Researchers are developing tests that could find, in a single sample of blood, signs of multiple kinds of cancer before they bring on symptoms and while they are most treatable.

How long will it be before these scientific miracles reach the people who need them most? One of the great promises of the Affordable Care Act was that Americans would receive better preventive care. Congress needs to honor this promise by providing a smoother pathway to coverage.

Karen Tumulty is a Washington Post associate editor and columnist covering national politics. Her previous article was “The honeymoon is over. Now Harris must make her case.”